Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intrinsic cancer cell phosphoinositide 3-kinase δ regulates fibrosis and vascular development in cholangiocarcinoma

  • Bou Malham, Vanessa
  • Benzoubir, Nassima
  • Vaquero, Javier
  • Desterke, Christophe
  • Xuan Song, Pei
  • Gonzalez-Sanchez, Ester
  • Arbelaiz, Ander
  • Jacques, Sophie
  • Valentin, Emanuel Di
  • Rahmouni, Souad
  • Zea Tan, Tuan
  • Samuel, Didier
  • Thiery, Jean Paul
  • Sebagh, Mylène
  • Fouassier, Laura
  • Gassama-Diagne, Ama
[Background & Aims]: The class I- phosphatidylinositol-3 kinases (PI3Ks) signalling is dysregulated in almost all human cancers whereas the isoform-specific roles remain poorly investigated. We reported that the isoform δ (PI3Kδ) regulated epithelial cell polarity and plasticity and recent developments have heightened its role in hepatocellular carcinoma (HCC) and solid tumour progression. However, its role in cholangiocarcinoma (CCA) still lacks investigation. [Approach & Results]: Immunohistochemical analyses of CCA samples reveal a high expression of PI3Kδ in the less differentiated CCA. The RT-qPCR and immunoblot analyses performed on CCA cells stably overexpressing PI3Kδ using lentiviral construction reveal an increase of mesenchymal and stem cell markers and the pluripotency transcription factors. CCA cells stably overexpressing PI3Kδ cultured in 3D culture display a thick layer of ECM at the basement membrane and a wide single lumen compared to control cells. Similar data are observed in vivo, in xenografted tumours established with PI3Kδ-overexpressing CCA cells in immunodeficient mice. The expression of mesenchymal and stemness genes also increases and tumour tissue displays necrosis and fibrosis, along with a prominent angiogenesis and lymphangiogenesis, as in mice liver of AAV8-based-PI3Kδ overexpression. These PI3Kδ-mediated cell morphogenesis and stroma remodelling were dependent on TGFβ/Src/Notch signalling. Whole transcriptome analysis of PI3Kδ using the cancer cell line encyclopedia allows the classification of CCA cells according to cancer progression. [Conclusions]: Overall, our results support the critical role of PI3Kδ in the progression and aggressiveness of CCA via TGFβ/src/Notch-dependent mechanisms and open new directions for the classification and treatment of CCA patients., VBM was supported by A.S.C. s.a.r.l, Liban, LF receives financial support from ITMO Cancer of Aviesan within the 2021–2030 Cancer Control Strategy framework on funds administered by Inserm, INCa_16428, ANR-17-CE14-0013-01 and belongs to a team supported by the Fondation pour la Recherche Médicale (Equipe FRM 2020 no. EQU202003010517). AA is supported by the Fondation pour la Recherche Médicale (FRM SPF201809007054) and by Les Entreprises contre le Cancer Paris – Île-de-France (GEFLUC_2019). JV is the recipient of the following postdoctoral fellowships from the Spanish Association for the Study of the Liver (AEEH), the Fondation ARC (PDF2014601431) and the LABEX PLAS@PAR (Reference ANR-11-IDEX-0004-02). JV was funded by the Spanish Ministry for Science and Innovation (MCIN: ‘Ramón y Cajal’ Program RYC2021-034121-I). JV, EGS and LF are members of the European Network for the Study of Cholangiocarcinoma (ENSCCA) and participate in the initiative COST action EURO-CHOLANGIO-NET (CA18122). AGD is supported by funding from the La Ligue contre le Cancer., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TGFβ-induced circLTBP2 predicts a poor prognosis in intrahepatic cholangiocarcinoma and mediates gemcitabine resistance by sponging miR-338-3p

  • Louis, Corentin
  • Ferlier, Tanguy
  • Leroux, Raffaële
  • Pineau, Raphaël
  • Desoteux, Matthis
  • Papoutsoglou, Panagiotis
  • Leclerc, Delphine
  • Angenard, Gaëlle
  • Vaquero, Javier
  • Macías, Rocío I.R.
  • Edeline, Julien
  • Coulouarn, Cédric
[Background & Aims]: Intrahepatic cholangiocarcinoma (iCCA) is a deadly cancer worldwide with an increasing incidence and limited therapeutic options. Therefore, there is an urgent need to open the field to new concepts for identifying clinically relevant therapeutic targets and biomarkers. Here, we explored the role and the clinical relevance of circular RNA (circRNA) circLTBP2 in iCCA., [Methods]: Transforming growth factor β (TGFβ)-regulated circRNAs were identified by dedicated microarrays in human HuCC-T1 iCCA cell line, and their clinical relevance was evaluated in independent cohorts of patients. Gain and loss of function of circLTBP2 combined with functional tests was performed in vitro and in vivo in mice. RNA pulldown, microRNA sequencing, and RNA immunoprecipitation were performed to explore the sponging activity of circLTBP2., [Results]: CircLTBP2 (has_circ_0032603) was identified as a novel TGFβ-induced circRNA in several cholangiocarcinoma cell lines. CircLTBP2 promotes tumour cell proliferation, migration, and resistance to gemcitabine-induced apoptosis in vitro and tumour growth in vivo. Mechanistically, circLTBP2 acts as a competitive RNA regulating notably the activity of the tumour suppressor microRNA miR-338-3p, leading to the overexpression of its pro-metastatic targets. The restoration of miR-338-3p levels in iCCA cells reversed the pro-tumourigenic effects driven by circLTBP2, including the resistance to gemcitabine-induced apoptosis. In addition, circLTBP2 expression predicted a reduced survival, as detected in not only tumour tissues but also serum extracellular vesicles isolated from patients with iCCA., [Conclusions]: CircLTBP2 is a novel effector of the pro-tumourigenic arm of TGFβ and a clinically relevant biomarker easily detected from liquid biopsies in iCCA., This work was supported by Inserm, Université de Rennes 1, CLCC Eugène Marquis, and ITMO Cancer AVIESAN (Alliance Nationale pour les Sciences de la Vie et de la Santé) dans le cadre du Plan cancer (Non-coding RNA in cancerology: fundamental to translational), Ligue contre le cancer (CD22, CD29, CD35, CD44, CD49, CD85), and Ligue nationale contre le cancer, and received financial support from ITMO Cancer of AVIESAN within the framework of the 2021–2030 Cancer Control Strategy, on funds administered by Inserm. This work has been supported by the Fondation ARC pour la recherche sur le cancer and has received grants from the French Ministry of Health and the French National Cancer Institute, PRTK20-136, PLBIO21-212, CHU Rennes, CLCC Eugène Marquis, Rennes. JV was funded by the Spanish Ministry for Science and Innovation (MCIN: ‘Ramon y Cajal’ program RYC2021-034121-I). CC, JE, JV, and RIRM are members of the European Network for the Study of Cholangiocarcinoma (ENSCCA) and participate in the initiative COST Action EURO-CHOLANGIO-NET granted by the COST Association (CA18122)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche

  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Caballero-Díaz, Daniel
  • Grzelak, Jan
  • Fusté, Noel P.
  • Bertran, Esther
  • Amengual, Josep
  • Garcia-Saez, Juan
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Alay, Ania
  • Coulouarn, Cédric
  • Calero-Pérez, Silvia
  • Valdecantos, Pilar
  • Valverde, Ángela M.
  • Sánchez, Aranzazu
  • Herrera, Blanca
  • Fabregat, Isabel
Liver fibrosis is the consequence of chronic liver injury in the presence of an inflammatory component. Although the main executors of this activation are known, the mechanisms that lead to the inflammatory process that mediates the production of pro-fibrotic factors are not well characterized. Epidermal growth factor receptor (EGFR) signaling in hepatocytes is essential for the regenerative processes of the liver; however, its potential role in regulating the fibrotic niche is not yet clear. Our group generated a mouse model that expresses an inactive truncated form of the EGFR specifically in hepatocytes (ΔEGFR mice). Here, we have analyzed the response of WT and ΔEGFR mice to chronic treatment with carbon tetrachloride (CCl4), which induces a pro-inflammatory and fibrotic process in the liver. The results indicated that the hallmarks of liver fibrosis were attenuated in CCl4-treated ΔEGFR mice when compared with CCl4-treated WT mice, coinciding with a faster resolution of the fibrotic process and ameliorated damage. The absence of EGFR activity in hepatocytes induced changes in the pattern of immune cells in the liver, with a notable increase in the population of M2 macrophages, more related to fibrosis resolution, as well as in the population of lymphocytes related to eradication of the damage. Transcriptome analysis of hepatocytes, and secretome studies of extracellular media from in vitro experiments, allowed us to elucidate the specific molecular mechanisms regulated by EGFR that mediate hepatocyte production of both pro-fibrotic and pro-inflammatory mediators; these have consequences for the deposition of extracellular matrix proteins, as well as for the immune microenvironment. Overall, our study uncovered novel mechanistic insights regarding EGFR kinase-dependent actions in hepatocytes that reveal its key role in chronic liver damage., This work was supported by (i) Fundacion Ramon Areces 20th National Competition for Scientific and Technical Research in Life and Matter Science 2020, grant # CIVP20A6593, to IF; (ii) Ministerio de Ciencia e Innovación (MICINN), Spain, which is part of the Agencia Estatal de Investigación (AEI), through (a) the Retos Investigación grants, numbers: RTI2018-094079-B-100 (co-funded by European Regional Development Fund, ERDF, a way to build Europe) to IF; PID2021-122551OB-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to IF; RTI2018-099098-B-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to AS/BH; PID-2021-122766OB-100 funded by MCIN/AEI/10.13039/501100011033 to AMV; and (b) the Retos Colaboración grant number RTC2019-007125-1 to IF. JV was funded by MICINN/AEI, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and ‘Ramon y Cajal’ program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank CERCA Programme/Generalitat de Catalunya for institutional support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hepatic Stellate Cells Functional Heterogeneity in Liver Cancer

  • Sererols-Viñas, Laura
  • Garcia-Vicién, Gemma
  • Ruiz-Blázquez, Paloma
  • Lee, Ting-Fang
  • Lee, Youngmin A.
  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Moles, Anna
  • Filliol, Aveline
  • Affò, Silvia
Hepatic stellate cells (HSCs) are the liver's pericytes, and play key roles in liver homeostasis, regeneration, fibrosis, and cancer. Upon injury, HSCs activate and are the main origin of myofibroblasts and cancer-associated fibroblasts (CAFs) in liver fibrosis and cancer. Primary liver cancer has a grim prognosis, ranking as the third leading cause of cancer-related deaths worldwide, with hepatocellular carcinoma (HCC) being the predominant type, followed by intrahepatic cholangiocarcinoma (iCCA). Moreover, the liver hosts 35% of all metastatic lesions. The distinct spatial distribution and functional roles of HSCs across these malignancies represent a significant challenge for universal therapeutic strategies, requiring a nuanced and tailored understanding of their contributions. This review examines the heterogeneous roles of HSCs in liver cancer, focusing on their spatial localization, dynamic interactions within the tumor microenvironment (TME), and emerging therapeutic opportunities, including strategies to modulate their activity, and harness their potential as targets for antifibrotic and antitumor interventions., S.A. is funded by the RYC2022-036321-I, MCIN/AEI/10.13039/501100011033/FEDER, Project PID2021-124694OA-I00, and The European Union grant agreement 101077312*. This work was also funded, in part, through the NIH/NCI Cancer Center Support Core Grant P30 CA008748 to A.A.F.; Y.A.L. is supported by 1R01DK133512 RSG-22-061-01-MM; A.M. is funded by MCIN/AEI/10.13039/501100011033/FEDER, UE through the project grant PID2021-123652OB-I00 and Pfizer grant #77131383; P.R.B. is funded by Ministerio de Universidades fellowships FPU19/05357. J.V. is funded by AEI, MICIN, through the project grant PID2022-141984OB-I00 and the “Ramon y Cajal” program RYC2021-034121-I.Figures Created in BioRender.*Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epithelial to Mesenchymal Transition Transcriptional Regulator ZEB1 in Liver Cancer: Oncogenic Roles and Therapeutic Potential

  • Gonzalez-Sanchez, Ester
  • Roldán-Hernández, Carlos Andrés
  • Martín-Ramírez, Ana
  • García-Collado, Lucía
  • Fouassier, Laura
  • Vaquero, Javier
Zinc finger E-box binding homeobox 1 (ZEB1) is a member of the zinc finger homeodomain transcription factor family, with a pivotal role in regulating the epithelial to mesenchymal transition (EMT) process. Increasing evidence suggests that ZEB1 is overexpressed in liver tumors, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), and it correlates with advanced disease features and reduced overall survival. Here, we examine ZEB1 molecular functions, regulatory networks and contribution to tumorigenesis. We also discuss the emerging therapeutic strategies and future research directions aimed at targeting the ZEB1 molecular network to improve the outcome of liver cancer patients., This work was supported by Agencia Estatal de Investigación (AEI), Ministry of Science and Innovation (MICIN), Spain, cofounded by FEDER funds/Development Fund—a way to build Europe, grant numbers PID2022-141984OB-I00 and RYC2021-034121-I, and by Fundación Memoria de D. Samuel Solorzano Barruso, grant number FS/14-2023, to J.V. This work was also funded by «Escalera de Excelencia» of the Education Ministry of the Castilla y León autonomous government, plus the European Regional Development Fund (CLU-2023-2-01). J.V. was funded by AEI and MICIN, through the “Ramon y Cajal” program RYC2021-034121-I. C.A.R.-H. was funded by CSIC through a JAE-PRE fellowship (JAEPR23102). L.G.-C. was funded by AEI, MICIN through the PID2022-141984OB-I00 grant. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain., Peer reviewed